Plasma proteome profiling of atherosclerotic disease manifestations reveals elevated levels of the cytoskeletal protein vinculin

Journal of Proteomics

Volumn 101, Issue , 2014, Pages 141-153

  Kristensen, Lars P ^a,b   Larsen, Martin R ^b   Mickley, Hans ^a,b   Saaby, Lotte ^a   Diederichsen, Axel C P ^a,b   Lambrechtsen, Jess ^a   Rasmussen, Lars M ^a,b   Overgaard, Martin ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Atherosclerosis; Immunoassay; Plasma biomarker; Proteomics; Selected reaction monitoring; Vinculin

Indexed keywords

APOLIPOPROTEIN A; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN; SERUM AMYLOID A; VINCULIN; BIOLOGICAL MARKER; CYTOSKELETON PROTEIN; PLASMA PROTEIN; PROTEOME;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ADHESION; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CONTROLLED STUDY; CYTOSKELETON; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; IMMUNOASSAY; ISCHEMIC HEART DISEASE; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; AGED; BLOOD; METABOLISM; METABOLOME; UPREGULATION;

AGED; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD PROTEINS; CYTOSKELETAL PROTEINS; FEMALE; HUMANS; MALE; METABOLOME; MIDDLE AGED; PROTEOME; UP-REGULATION; VINCULIN;

EID: 84896806206     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2013.12.011     Document Type: Article

References (49)

1. Abd T.T., Eapen D.J., Bajpai A., Goyal A., Dollar A., Sperling L. The role of C-reactive protein as a risk predictor of coronary atherosclerosis: implications from the JUPITER trial. Curr Atheroscler Rep Apr 2011, 13(2):154-161.
2. Enkhmaa B., Anuurad E., Zhang W., Tran T., Berglund L. Lipoprotein(a): genotype-phenotype relationship and impact on atherogenic risk. Metab Syndr Relat Disord Dec 2011, 9(6):411-418.
3. Cangemi C., Skov V., Poulsen M.K., Funder J., Twal W.O., Gall M.A., et al. Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes. Clin Chem Nov 2011, 57(11):1556-1565.
4. Gerszten R.E., Asnani A., Carr S.A. Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics. Circ Res Aug 5 2011, 109(4):463-474.
5. Vasan R.S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation May 16 2006, 113(19):2335-2362.
6. Duran M.C., Martin-Ventura J.L., Mas S., Barderas M.G., Darde V.M., Jensen O.N., et al. Characterization of the human atheroma plaque secretome by proteomic analysis. Methods Mol Biol 2007, 357:141-150.
7. de la Cuesta F., Barderas M.G., Calvo E., Zubiri I., Maroto A.S., Darde V.M., et al. Secretome analysis of atherosclerotic and non-atherosclerotic arteries reveals dynamic extracellular remodeling during pathogenesis. J Proteomics Jun 6 2012, 75(10):2960-2971.
8. Donahue M.P., Rose K., Hochstrasser D., Vonderscher J., Grass P., Chibout S.D., et al. Discovery of proteins related to coronary artery disease using industrial-scale proteomics analysis of pooled plasma. Am Heart J Sep 2006, 152(3):478-485.
9. Haas B., Serchi T., Wagner D.R., Gilson G., Planchon S., Renaut J., et al. Proteomic analysis of plasma samples from patients with acute myocardial infarction identifies haptoglobin as a potential prognostic biomarker. J Proteomics Dec 10 2011, 75(1):229-236.
10. Cubedo J., Padro T., Alonso R., Cinca J., Mata P., Badimon L. Differential proteomic distribution of TTR (pre-albumin) forms in serum and HDL of patients with high cardiovascular risk. Atherosclerosis May 2012, 222(1):263-269.
11. Palmisano G., Lendal S.E., Engholm-Keller K., Leth-Larsen R., Parker B.L., Larsen M.R. Selective enrichment of sialic acid-containing glycopeptides using titanium dioxide chromatography with analysis by HILIC and mass spectrometry. Nat Protoc Dec 2010, 5(12):1974-1982.
12. Palmisano G., Parker B.L., Engholm-Keller K., Lendal S.E., Kulej K., Schulz M., et al. A novel method for the simultaneous enrichment, identification, and quantification of phosphopeptides and sialylated glycopeptides applied to a temporal profile of mouse brain development. Mol Cell Proteomics Nov 2012, 11(11):1191-1202.
13. Barascuk N., Genovese F., Larsen L., Byrjalsen I., Zheng Q., Sun S., et al. A MMP derived versican neo-epitope is elevated in plasma from patients with atherosclerotic heart disease. Int J Clin Exp Med 2013, 6(3):174-184.
14. Diederichsen A.C., Sand N.P., Norgaard B., Lambrechtsen J., Jensen J.M., Munkholm H., et al. Discrepancy between coronary artery calcium score and HeartScore in middle-aged Danes: the DanRisk study. Eur J Prev Cardiol Jun 2012, 19(3):558-564.
15. Saaby L., Poulsen T.S., Hosbond S., Larsen T.B., Pyndt Diederichsen A.C., Hallas J., et al. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med Sep 2013, 126(9):789-797.
16. Larsen M.R., Jensen S.S., Jakobsen L.A., Heegaard N.H. Exploring the sialiome using titanium dioxide chromatography and mass spectrometry. Mol Cell Proteomics Oct 2007, 6(10):1778-1787.
17. Perkins D.N., Pappin D.J., Creasy D.M., Cottrell J.S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis Dec 1999, 20(18):3551-3567.
18. Navarro P., Vazquez J. A refined method to calculate false discovery rates for peptide identification using decoy databases. J Proteome Res Apr 2009, 8(4):1792-1796.
19. Cox J., Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol Dec 2008, 26(12):1367-1372.
20. Petersen T.N., Brunak S., von H.G., Nielsen H. SignalP 4.0: discriminating signal peptides from transmembrane regions. Nat Methods 2011, 8(10):785-786.
21. Maclean B., Tomazela D.M., Shulman N., Chambers M., Finney G.L., Frewen B., et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics Apr 1 2010, 26(7):966-968.
22. Tabb D.L., Vega-Montoto L., Rudnick P.A., Variyath A.M., Ham A.J., Bunk D.M., et al. Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res Feb 5 2010, 9(2):761-776.
23. Ziegler W.H., Gingras A.R., Critchley D.R., Emsley J. Integrin connections to the cytoskeleton through talin and vinculin. Biochem Soc Trans Apr 2008, 36(Pt 2):235-239.
24. DeMali K.A., Barlow C.A., Burridge K. Recruitment of the Arp2/3 complex to vinculin: coupling membrane protrusion to matrix adhesion. J Cell Biol Dec 9 2002, 159(5):881-891.
25. Frolova E.G., Pluskota E., Krukovets I., Burke T., Drumm C., Smith J.D., et al. Thrombospondin-4 regulates vascular inflammation and atherogenesis. Circ Res Nov 26 2010, 107(11):1313-1325.
26. Stenina O.I., Topol E.J., Plow E.F. Thrombospondins, their polymorphisms, and cardiovascular disease. Arterioscler Thromb Vasc Biol Sep 2007, 27(9):1886-1894.
27. Kamstrup P.R., Benn M., Tybjaerg-Hansen A., Nordestgaard B.G. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation Jan 15 2008, 117(2):176-184.
28. Kamstrup P.R., Tybjaerg-Hansen A., Steffensen R., Nordestgaard B.G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA Jun 10 2009, 301(22):2331-2339.
29. Virani S.S., Brautbar A., Davis B.C., Nambi V., Hoogeveen R.C., Sharrett A.R., et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation Jan 17 2012, 125(2):241-249.
30. Bennet A., Di A.E., Erqou S., Eiriksdottir G., Sigurdsson G., Woodward M., et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med Mar 24 2008, 168(6):598-608.
31. Danesh J., Collins R., Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation Sep 5 2000, 102(10):1082-1085.
32. Johnson B.D., Kip K.E., Marroquin O.C., Ridker P.M., Kelsey S.F., Shaw L.J., et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation Feb 17 2004, 109(6):726-732.
33. Kosuge M., Ebina T., Ishikawa T., Hibi K., Tsukahara K., Okuda J., et al. Serum amyloid A is a better predictor of clinical outcomes than C-reactive protein in non-ST-segment elevation acute coronary syndromes. Circ J Feb 2007, 71(2):186-190.
34. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med Mar 23 2000, 342(12):836-843.
35. Kuzyk M.A., Smith D., Yang J., Cross T.J., Jackson A.M., Hardie D.B., et al. Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol Cell Proteomics Aug 2009, 8(8):1860-1877.
36. Insull W. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med Jan 2009, 122(1 Suppl.):S3-S14.
37. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature May 19 2011, 473(7347):317-325.
38. Herlitz J., Wireklintsundstrom B., Bang A., Berglund A., Svensson L., Blomstrand C. Early identification and delay to treatment in myocardial infarction and stroke: differences and similarities. Scand J Trauma Resusc Emerg Med 2010, 18:48.
39. Jacquet S., Yin X., Sicard P., Clark J., Kanaganayagam G.S., Mayr M., et al. Identification of cardiac myosin-binding protein C as a candidate biomarker of myocardial infarction by proteomics analysis. Mol Cell Proteomics Dec 2009, 8(12):2687-2699.
40. Silbiger V.N., Luchessi A.D., Hirata R.D., Neto L.G., Pastorelli C.P., Ueda E.K., et al. Time course proteomic profiling of human myocardial infarction plasma samples: an approach to new biomarker discovery. Clin Chim Acta May 12 2011, 412(11-12):1086-1093.
41. de la Cuesta F., Zubiri I., Maroto A.S., Posada M., Padial L.R., Vivanco F., et al. Deregulation of smooth muscle cell cytoskeleton within the human atherosclerotic coronary media layer. J Proteomics Apr 26 2013, 82:155-165.
42. Feig J.E., Vengrenyuk Y., Reiser V., Wu C., Statnikov A., Aliferis C.F., et al. Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome. PLoS One 2012, 7(6):e39790.
43. Sato Y., Fujiwara H., Takatsu Y. Cardiac troponin and heart failure in the era of high-sensitivity assays. J Cardiol Sep 2012, 60(3):160-167.
44. Steenbergen C., Hill M.L., Jennings R.B. Cytoskeletal damage during myocardial ischemia: changes in vinculin immunofluorescence staining during total in vitro ischemia in canine heart. Circ Res Apr 1987, 60(4):478-486.
45. Meyer T., Brink U., Unterberg C., Stohr S., Kreuzer H., Buchwald A.B. Expression of meta-vinculin in human coronary arteriosclerosis is related to the histological grade of plaque formation. Atherosclerosis Nov 1994, 111(1):111-119.
46. Rocchiccioli S., Pelosi G., Rosini S., Marconi M., Viglione F., Citti L., et al. Secreted proteins from carotid endarterectomy: an untargeted approach to disclose molecular clues of plaque progression. J Transl Med Oct 16 2013, 11(1):260.
47. King V.L., Thompson J., Tannock L.R. Serum amyloid A in atherosclerosis. Curr Opin Lipidol Aug 2011, 22(4):302-307.
48. Varki A., Lowe J.B. Biological roles of glycans 2009.
49. Palmisano G., Lendal S.E., Larsen M.R. Titanium dioxide enrichment of sialic acid-containing glycopeptides. Methods Mol Biol 2011, 753:309-322.